BDX - Becton Dickinson and Company (BDX) Q1 2024 Earnings Call Transcript
2024-02-01 11:41:06 ET
Becton, Dickinson and Company (BDX)
Q1 2024 Earnings Conference Call
February 1, 2024 08:00 AM ET
Company Participants
Greg Rodetis - SVP, Treasurer & Head of IR
Tom Polen - Chairman, President & CEO
Christopher DelOrefice - EVP & CFO
Michael Garrison - EVP & President, Medical Segment
Dave Hickey - EVP & President, Life Sciences segment
Conference Call Participants
Rick Wise - Stifel
Travis Steed - Bank of America
Vijay Kumar - Evercore ISI
Lawrence Biegelsen - Wells Fargo
Robbie Marcus - JPMorgan
Patrick Wood - Morgan Stanley
Matthew Miksic - Barclays
Presentation
Operator
Hello, and welcome to BD's First Fiscal Quarter 2024 Earnings Call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website investors.bd.com or by phone at 800-688-7339 for domestic calls and area code +1 402-220-1347 for international calls. For today's call, all parties have been placed on a listen-only mode until the question-and-answer session.
I will now turn the call over to Greg Rodetis, Senior Vice President, Treasurer and Head of Investor Relations.
Greg Rodetis
Good morning, and welcome to BD's earnings call. I'm Greg Rodetis, Senior Vice President, Treasurer and Head of Investor Relations. On behalf of the BD team, thank you for joining us. This call is being made available via audio webcast at bd.com. Earlier this morning, BD released its results for the first quarter of fiscal 2024. We also posted an earnings presentation that provides additional details on our business, strategy and performance. The press release and presentation can be accessed on the IR website at investors.bd.com.
Leading today's calls are Tom Polen, BD's Chairman, Chief Executive Officer and President; and Chris DelOrefice, Executive Vice President and Chief Financial Officer. Tom will provide highlights of our performance and the continued execution of our BD 2025 strategy. Chris will then provide additional details on our Q1 financial performance and our updated guidance for fiscal 2024. Following the prepared remarks, Tom and Chris will be joined for Q&A by our segment presidents, Mike Garrison, President of the Medical segment; Dave Hickey, President of the Life Sciences segment; and Rick Byrd, President of the Interventional segment.
Before we get started, I want to remind you that we will be making forward-looking statements. I encourage you to read the disclaimer in our earnings release and the disclosures in our SEC filings, which are both available on the Investor Relations website. Unless otherwise specified, all comparisons will be on a year-over-year basis versus the relevant period. Revenue percentage changes are on an FX-neutral basis unless otherwise noted. When we refer to any given period, we are referring to the fiscal period unless we specifically noted as a calendar period. I would also call your attention to the non-GAAP reconciliations included in the appendices of the press release and earnings presentation.
With that, I’m very pleased to turn it over to Tom.
Tom Polen
Thanks, Greg. Good morning, everyone, and thank you for joining us. Earlier today, we reported our results for the first quarter. Overall, we executed Q1 as expected. Total revenue growth was largely in line with our expectations. And on the bottom line, adjusted EPS was ahead of our expectations due to good execution on our margin goals through our BD Excellence operating system and the timing of discrete tax item....
Becton, Dickinson and Company (BDX) Q1 2024 Earnings Call Transcript